Finally, early phase studies with a PD-1 inhibitor with colony stimulating factor 1 receptor (CSFR) inhibitors have been initiated in solid tumors and melanoma (NCT02526017, NCT02452424); however, one of the trials (NCT02452424) has been terminated due to inadequate evidence of clinical efficacy. This evidence concerns the gene PDCD1 and melanoma.